Jay Trivedi

Dr. Jay Trivedi


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JTJay Trivedi
Jay Trivedi
MMMahesh Mohan
Mahesh Mohan
SBSiddappa Byrareddy
Siddappa Byrareddy
Development of novel antiviral molecules from the beginning costs an average of $350 million to $2 billion per drug, and the journey from the laboratory to the clinic takes about 10–15 years. Utilization of drug repurposing approaches has generated substantial interest in order to overcome these drawbacks. A drastic reduction in the failure rate, which otherwise is ~92%, is achieved with the drug repurposing approach. The recent exploration of the drug repurposing approach to combat the COVID-19 pandemic has further validated the fact that it is more beneficial to reinvestigate the in-practice drugs for a new application instead of designing novel drugs. The first successful example of drug repurposing is zidovudine (AZT), which was developed as an anti-cancer agent in the 1960s and was later approved by the US FDA as an anti-HIV therapeutic drug in the late 1980s after fast track clinical trials. Since that time, the drug repurposing approach has been successfully utilized to develop effective therapeutic strategies against a plethora of diseases. Hence, an extensive application of the drug repurposing approach will not only help to fight the current pandemics more efficiently but also predict and prepare for newly emerging viral infections. In this review, we discuss in detail the drug repurposing approach and its advancements related to viral infections such as Human Immunodeficiency Virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

21 January 2020 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
JTJay Trivedi
Jay Trivedi
DMDinesh Mahajan
Dinesh Mahajan
RJRussell J. Jaffe
Russell J. Jaffe
AAArpan Acharya
Arpan Acharya
DMDebashis Mitra
Debashis Mitra
SBSiddappa Byrareddy
Siddappa Byrareddy


1 December 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JTJay Trivedi
Jay Trivedi
APAfsana Parveen
Afsana Parveen
FRFarhana Rozy
Farhana Rozy
AMAlapani Mitra
Alapani Mitra
CBChandralata Bal
Chandralata Bal
ASAshoke Sharon
Ashoke Sharon

1 March 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
SSSurya Shrivastava
Surya Shrivastava
JTJay Trivedi
Jay Trivedi
DMDebashis Mitra
Debashis Mitra
Human Immunodeficiency Virus-1 (HIV-1) encodes a 27 kDa Negative Factor or Nef protein, which is increasingly proving to be a misnomer. Nef seems to be crucial for AIDS progression as individuals infected with nef-deleted strain of HIV were reported to become Long Term Non Progressors (LTNP). These findings necessitate tracing of Nef's footprint on landscape of cellular transcriptome favoring HIV-1 pathogenesis. We have tried to explore effect of Nef on cellular gene expression profile in conjunction with rest of HIV-1 proteins. Our results show that 237 genes are differentially regulated due to the presence of Nef during infection, which belong to several broad categories like "signaling", "apoptosis", "transcription" and "lipid metabolism" in gene ontology analysis. Furthermore, our results show that Nef causes disruption of lipid content in HIV-1 infected T cells. Molecular inhibitors of lipid metabolism like Atorvastatin and Ranolazine were found to have profound effect on wild type virus as compared to nef-deleted HIV-1. Thus our results suggest that interference in lipid metabolism is a potential mechanism through which Nef contributes in enhancing HIV-1 pathogenesis.

1 August 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
NJNisha Grandhi Jayaprakash
Nisha Grandhi Jayaprakash
ASAmrita Singh
Amrita Singh
RVRahul Vivek
Rahul Vivek
SYShivender Yadav
Shivender Yadav
SPSanmoy Pathak
Sanmoy Pathak
ASAvadhesha Surolia
Avadhesha Surolia
N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120). Carbohydrate-binding proteins, particularly mannose-binding lectins, have also been shown to bind these glycans. Despite their therapeutic potency, their ability to cause lymphocyte proliferation limits their application. In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent. Extensive isothermal titration calorimetry experiments reveal that the lectin was sensitive to the length and branching of mannooligosaccharides and thereby the total valency. Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites. This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity. Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.